The association between coronary artery disease and nonalcoholic fatty liver disease and noninvasive imaging methods
More details
Hide details
Selcuk University, Medical Faculty, Turkey
Department of Radiology, Medical Faculty of Adnan Menderes University, Turkey
Online publication date: 2019-12-05
Publication date: 2019-12-05
Electron J Gen Med 2019;16(6):em165
Coronary artery disease (CAD) is the number one cause of death globally and imaging plays a pivotal role in the diagnosis and management of CAD. With the improvements in technology, noninvasive imaging methods become more widely used in the management of CAD. Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome which affects a substantial proportion of general population and is a component of the metabolic syndrome (MetS). Histopathologic analysis is the reference standard to detect and quantify fat in the liver, but results are vulnerable to sampling error. Imaging can be repeated regularly and allows assessment of the entire liver, thus avoiding sampling error so imaging is in key role in the management of NAFLD as in CAD. As NAFLD is a component of MetS, it is associated with increased risk for CAD. Recent studies suggest a more complex picture of the interrelation between NAFLD, MetS and CAD, and raised the possibility that NAFLD might not only be a marker but also an early mediator for CAD. So early detection of NAFLD and its management with noninvasive imaging methods can be very crucial in the control of CAD which is the number one cause of death globally.
World Health Organization (WHO) international media center fact sheet no:317, updated january 2015.
American Heart Association. 2002 heart and stroke stastical update. Dallas, TX; American Heart Association, 2001.
Cury RC, Nieman K, Shapiro MD, Butler J, Nomura CH, Ferencik M, et al. Comprehensive assessment of myocardial perfusion defects, regional wall motion, and left ventricular function by using 64-section multidetector CT. Radiology 2008;248:466-75. PMid:18641250 PMCid:PMC2797649.
Lipton M, Higgins CB, Boyd DP. Computed tomography of the heart; evaluation of anatomy and function. J Am Coll Cardiol 1985;5(Suppl 1):55-69.
Dewey M, Zimmermann E, Deissenrieder F, Laule M, Dübel HP, Schlattmann P, et al. “Noninvasive coronary anjiography by 320-row computed tomography with lower radiation exposure and maintained diagnostic accuracy: comparison of results with cardiac catheterization in a head-to-head pilot investigation.” Circulation 2009;120:867-75. PMid:19704093.
Achenbach S, Marwan M, Ropers D, Schepis T, Pflederer T, Anders K, et al. “Coronary computed tomography angiography with a consistent dose below 1 mSv using prospective electrocardiogram triggered high-pitch spiral acquisition. Eur Heart J 2010;31:340-6. PMid:19897497.
Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-32.
O’Malley PG, Taylor AJ, Gibbons RV, Feurstein IM, Jones DL, Vernalis M, et al. Rationale and design of Prospective Army Coronary Calcium (PACC) study: utility of electron beam computed tomography as a screening test for risk factor modification among young, asymptomatic, active-duty United States Army personel. Am Heart J 1999;137:932-41.
Nieman K, Oudkerk M, Rensing BJ, van Ooijen P, Munne A, van Geuns RJ, et al. Coronary angiography with multi-slice computed tomography. Lancet 2001;357(9256):599-603.
Topol EJ, Nissen SE. Our preoccupation with coronary luminology: the dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995;92:2333-42. PMid:7554219.
Becker CR, Nikolaou K, Muders M, Babaryka G, Crispin A, Schoepf UJ, et al. Ex vivo coronary atherosclerotic plaque characterization with multi-detector-row CT. Eur Radiol 2003;13:2094-8. PMid:12692681.
Rocha-Filho JA, Blankstein R, Shturman LD, Bezerra HG, Okada DR, Rogers IS, et al. Incremental value of adenosine-induced stres myocardial perfusion imaging with dual-source CT at cardiac CT angiography. Radiology 2010;254:410-9. PMid:20093513 PMCid:PMC2809927.
Techasith T, Cury RC. Stress myocardial CT perfusion. An update and future perspective. J Am Coll Cardiol Img 2011;4:905-16. PMid:21835384.
Reeder SB, Du YP, Lima JAC, Bluemke DA. Advanced cardiac MR imaging of ischemic heart disease. RadioGraphics 2001;21:1047-74. PMid:11452080.
Hundley GW, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic rosenance. JACC 2010;55:2614-62. PMid:20513610 PMCid:PMC3042771.
Parker MW, Iskandar A, Limone B, Perugini A, Kim H, Jones C, et al. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: a bivarite meta-analysis. Circ Cardiovasc Imaging 2012;5:700-7. PMid:23051888.
Dilsizian V, Bacharach SL, Beanlands R, Bergmann SR, Delbeke D, Gropler RJ, et al. ASNC imaging guidelines for nuclear cardiology procedures: PET myocardial perfusion and metabolism clinical imaging. J Nucl Cardiol 2009;16:651-81.
Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP, et al. American Society of Nuclear Cardiology imaging guidelines for nuclear cardiology procedures. Single photon-emission computed tomography. J Nucl Cardiol 2010;17:941-73. PMid:20552312.
Beanlands RS, Youssef G. Diagnosis and prognosis of coronary artery disease: PET is superior to SPECT: Pro. J Nucl Cardiol 2010;17:683-95. PMid:20589487.
Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH, et al. Prevalence of non-alcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003;9:1106-10. PMid:12717867 PMCid:PMC4611383.
Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016;65:1096-108. PMid:26856933 PMCid:PMC4943559.
Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty liver: Imaging patterns and pitfalls. RadioGraphics 2006;26:1637-53. PMid:17102041.
Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31. PMid:11961152.
Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis 2005;9:37-53. PMid:15763228.
Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Muller KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123(3):745-50. PMid:12198701.
Osawa H, Mory Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clic Ultrasound 1996;24(1):25-9.<25::AID-JCU4>3.0.CO;2-N.
Webb M, Yeshua H, Zelber-Sagi S, Santo E, Brazowski E, Halpern Z, Oren R. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol. 2009;192(4):909-14. PMid:19304694.
Mathiesen UL, Franzen LE, Aselius H, Resjö M, Jacabsson L, Foberg U, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002;34:516-22.
Yajima Y, Narui T, Ishii M, Abe R, Ohtsuki M, Goto Y, et al. Computed tomography in the diagnosis of fatty liver: total lipid content and computed tomography number. Tohoku J Exp Med 1982;136:337-42. PMid:7071850.
Panicek DM, Giess CS, Schwartz LH. Qualitative assessment of liver for fatty infiltration on contrast-enhanced CT: is muscle a better standart of reference than spleen? J Comput Assist Tomogr 1997;21:699-705. PMid:9294555.
Bydder GM, Chapman RW, Harry D, Bassan L, Sherlock S, Kreel L. Computed tomography attenuation values in fatty liver. J Comput Tomog 1981;5(1):33-5.
Lee SW, Park SH, Kim KW, Choi EK, Shin YM, Kim PN, et al. Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index. Radiology 2007;244:479-85. PMid:17641368.
Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, et al. Macrovesicular hepatic steatosis in liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006;239:105-12. PMid:16484355.
Raptopoulos V, Karellas A, Bernstein J, Reale FR, Constantinou C, Zawacki JK. Value of dual-energy CT in differentiating focal fatty infiltration of the liver from low-density masses. AJR Am J Roentgenol 1991;157:721-5. PMid:1892025.
Venkataraman S, Braga L, Semelka RC. Imaging the fatty liver. Magn Reson Imaging Clin N Am 2002;10:93-103.
Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-8. PMid:15339742.
Ma X, Holalkere NS, Kambadakore A, Kenudson MM, Hahn PF, Sahani DV. Imaging-based quantification of hepatic fat: methods and clinical applications. RadioGraphics 2009;29:1253-80. PMid:19755595.
Choji T. Evaluation of fatty liver changes and fatty degeneration in liver tumors by 1H-MRS. Nippon Igaku Hoghasen Gokkai Zasshi 1993;53:1408-14.
Loria P, Lonardo A, Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clincal Science 2008;115:1-12. PMid:19016656.
Grundy SM, Brewer Jr. HB, Cleeman JI, Smith Jr. SC, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, et al. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 2007;18:184-95. PMid:17296492.
Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007;191:235-40. PMid:16970951.
Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, et al. Relations between carotid artery wall thickness and liver histology insubjects with nonalcoholic fatty liver disease. Diabetes Care 2006;29:1325-30. PMid:16732016.
Villanova N, Moscatiello S, Ramili S, Bugianesi E, Magalotti D, Vanni E, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42(2):473-8. PMid:15981216.
Schwimmer JB, Deutsch R, Behling C, Lavine JE. Fatty liver as a determinant of atherosclerosis. Hepatology. 2005;42(Suppl):610A. PMid:16116629.
Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol 2011 14;17:3082-91. PMid:21799647 PMCid:PMC3132252.
Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J. Gastroenterol. 2015;21:6820-34. PMid:26078558 PMCid:PMC4462722.